Navigation Links
Confirmation of HGT Business Day - 18th November 2008
Date:11/12/2008

LEXINGTON, Massachusetts, November 12 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is holding an update on its Human Genetic Therapies (HGT) business for analysts and investors on 18th November 2008.

The seminar will include both an overview of Shire's overall HGT strategy and an in-depth look at the portfolio of HGT products both on the market and in development. The session will start at 9.00am (ET) and will finish at 2.30pm (ET). It is being held at Shire's HGT offices in Lexington, Massachusetts and will be webcast at http://www.shire.com. The seminar will not be providing an update on current trading. Further information on the seminar will be available on the Company's website, http://www.shire.com.

Presentations will be made by Angus Russell, Shire's Chief Executive, Sylvie Gregoire, President of Shire HGT and her senior team. In addition, Shire is pleased to announce that Pr. Marco Cicardi, M.D. University of Milan and Specialist in Angioedema will present on Hereditary Angioedema.

Notes to editors

Shire Plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shi
'/>"/>

SOURCE Shire Plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ProtoKinetix Receives Independent Confirmation of AAGP Anti-Inflammatory Action
2. Confirmation of Strong Growth Over the First Half of 2008
3. PointCross Releases Catalyst for Building Business-Ready SharePoint Solutions in 1/10th the Time
4. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
5. South Africas Minister of Minerals and Energy Welcomes Denham Capital Investment in BioTherm Energy to Develop Power Generation Business
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
8. ThromboGenics N.V.: Business Update
9. Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
10. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
11. Amgen to Webcast 2008 Business Review Meeting on November 7 From Millennium Hotel in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... 2014 The Latin American hardware encryption ... Latin America with analysis and forecast of revenue. This ... is expected to reach $2,366.8 million by 2018, at ... Browse through the TOC of the Latin American hardware ... in-depth analysis provided. It also provides a glimpse of ...
(Date:10/19/2014)... The Asian Automatic patient billing report ... and forecast of revenue. The Automatic patient billing market ... million by 2018, at a developing CAGR of 7.2% ... of the Asian Automatic patient billing market, to get ... provides a glimpse of the segmentation of this market ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... , ROCKVILLE, Md. , Aug. 6 ... today the appointment of Richard Douglas , Ph.D. to ... President, Corporate Development at Genzyme Corp.  As a leader of ... numerous acquisitions, licenses, joint ventures and strategic alliances as well ...
... Arizona State University researchers will get support from the ... next generations of lasers and infrared photodetectors. ... for an array of defense and commercial applications. ... Office grant through the defense department,s Multidisciplinary University Research ...
... Vicept Therapeutics, Inc., a privately held specialty biopharmaceutical company, announced ... the Company,s lead product V-101, a topical cream under investigation for ... , , ... crossover clinical trial of 22 patients with rosacea was designed to ...
Cached Biology Technology:NOVAVAX Elects Richard H. Douglas to its Board of Directors 2NOVAVAX Elects Richard H. Douglas to its Board of Directors 3Looking to leap forward on laser and photodetector technologies 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 2Vicept Therapeutics Announces Positive Clinical Study Results of V-101 for the Treatment of the Erythema of Rosacea 3
(Date:10/15/2014)... , Oct. 15, 2014 Sandata ... for home and community-based care, today announced it ... implementing Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™) ... is a home health company founded in 1996 ... . The study details ...
(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... 1, 2011 A pathway whereby bacteria communicate with ... Hebrew University of Jerusalem. The discovery has important implications ... bacteria in the body. Bacteria are known to ... of extracellular signalling molecules, said Prof. Sigal Ben-Yehuda of ...
... is known to have cancer-protective properties, and shift work ... production. Shift work has been thought to have important ... increased risk of several cancers including breast, endometrial, prostate, ... study, researchers at Brigham and Women,s Hospital (BWH) found ...
... SEATTLE Twelve graduate students from institutes throughout ... Harold M. Weintraub Graduate Student Award sponsored by the ... Nominations were solicited internationally; the winners were selected on ... their work. , The recipients, all advanced students at ...
Cached Biology News:Shift work may be associated with decreased risk of skin cancer 22011 Harold M. Weintraub Graduate Student Award recipients announced 22011 Harold M. Weintraub Graduate Student Award recipients announced 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: